Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

C4'-Substituted-2-Deoxyadenosine Analogs and Methods of Treating HIV

Posted Jun 09 2010 5:00pm

Description of Invention:
The invention describes a new use for C4'-methyl-2-dexoyadenosine, a nucleoside analog that has significant activity against HIV-1 and most strains of HIV previously shown to be resistant to other reverse transcriptase nucleoside inhibitor treatments. In vitro experimental results show substantial anti-HIV activity (blocked infectivity) with no observable cytotoxicity in cell culture. Mechanistic studies indicate that this compound blocks DNA synthesis by reverse transcriptase.

Applications:
Treatment and prevention of HIV infection

Advantages:
  • Nucleoside analog against HIV-1 reverse transcriptase with no observable cytotoxicity in cell culture
  • Potential new treatment for HIV-1 infections including infections by strains of HIV-1 that are resistant to nucleoside reverse transcriptase inhibitors


Development Status:
In vitro data can be provided upon request

Inventors:
Bao-Han C Vu (NCI)
Maqbool A Siddiqui (NCI)
Victor E Marquez (NCI)
Stephen H Hughes (NCI)


Patent Status:
HHS, Reference No. E-012-2008/0
PCT, Application No. PCT/US2008/012663 filed 10 Nov 2008
US, Application No. 12/741,873 filed 07 May 2010


Relevant Publication:
  1. Meeting Abstract: 8th Annual Symposium for Antiviral Resistance in Richmond, VA, November 11-14, 2007 (Can be provided upon request)


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute HIV Drug Resistance Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize C4' methyl- and C4'-ethyl-substituted-2-deoxyadenosine analogs Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Vaccines
In-vitro Data



For Additional Information Please Contact:
Sally Hu Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Email: hus@mail.nih.gov
Phone: 301-435-5606
Fax: 301-402-0220


Ref No: 1750

Updated: 06/2010

Post a comment
Write a comment:

Related Searches